Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 09 Nov 2015 Final results including data from expansion cohort, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015 (n=43).
    • 19 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 10 Nov 2014 Planned end date changed from 1 Nov 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top